Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells

Cancer Cell International

Volumn 9, Issue , 2009, Pages

  Leelawat, Kawin ^a,b   Narong, Siriluck ^a   Udomchaiprasertkul, Wandee ^b   Leelawat, Surang ^c   Tungpradubkul, Sumalee ^d  

^a RAJAVITHI HOSPITAL   (Thailand)

^b CHULABHORN RESEARCH INSTITUTE   (Thailand)

^c RANGSIT UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NICK END LABELING; NONHUMAN; WESTERN BLOTTING;

EID: 61349171307     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-9-3     Document Type: Article

References (22)

1. Sano T Shimada K Sakamoto Y Yamamoto J Yamasaki S Kosuge T One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality Ann Surg 2006, 244(2):240-247 1602147 16858186 10.1097/01.sla.0000217605.66519.38
2. Yang W-L Zhang X-C Zhang D-W Tong B-F Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma Hepatobiliary Pancreat Dis Int 2007, 6(6):631-635 18086631
3. Jordan K Kellner O Kegel T Schmoll H-J Grothey A Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers Clin Colorectal Cancer 2004, 4(1):46-50 10.3816/ CCC.2004.n.009 15207020
4. Woynarowski JM Faivre S Herzig MC Arnett B Chapman WG Trevino AV Raymond E Chaney SG Vaisman A Varchenko M Juniewicz PE Oxaliplatininduced damage of cellular DNA Mol Pharmacol 2000, 58(5):920-927 11040038
5. Androulakis N Aravantinos G Syrigos K Polyzos A Ziras N Tselepatiotis E Samonis G Kentepozidis N Giassas S Vamvakas L Georgoulias V Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: A multicenter phase II study Oncology 2006, 70(4):280-284 10.1159/ 000096249 17047399
6. Zhang CX Huang S Xu N Fang JW Shen P Bao YH Mou BH Shi MG Zhong XL Xiong PJ Phase II study of epirubicin plus oxaliplatin and infusional 5- fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer Anticancer Drugs 2007, 18(5):581-586 10.1097/CAD.0b013e3280146296 17414627
7. Nehls O Oettle H Hartmann JT Hofheinz RD Hass HG Horger MS Koppenhöfer U Hochhaus A Stieler J Trojan J Gregor M Klump B Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: A prospective multicentre phase II trial Br J Cancer 2008, 98(2):309-315 10.1038/sj.bjc.6604178 18182984
8. Leelawat K Leelawat S Narong S Hongeng S Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion World J Gastroenterol 2007, 13(10):1561-1568 17461449
9. Lee S Choi E-J Jin C Kim D-H Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line Gynecol Oncol 2005, 97(1):26-34 10.1016/j.ygyno.2004.11.051 15790433
10. Kim S Lee T-J Park J-W Kwon TK Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells J Cell Biochem 2008, 105(4):971-979 10.1002/jcb.21905 18767116
11. Gera JF Mellinghoff IK Shi Y Rettig MB Tran C Hsu JH Sawyers CL Lichtenstein AK AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression J Biol Chem 2004, 279(4);2737-2746 10.1074/jbc.M309999200 14576155
12. Troiani T Lockerbie O Morrow M Ciardiello F Eckhardt SG Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases Mol Cancer Ther 2006, 5(7):1883-1894 10.1158/1535-7163.MCT-06-0055 16891475
13. Patel T Singh P Cholangiocarcinoma: Emerging approaches to a challenging cancer Curr Opin Gastroenterol 2007, 23(3):317-323 10.1097/ MOG.0b013e3280495451 17414849
14. Bidoli P Zilembo N Cortinovis D Mariani L Isa L Aitini E Cullurà D Pari F Nova P Mancin M Formisano B Bajetta E Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study Ann Oncol 2007, 18(3):461-467 10.1093/annonc/mdl415 17110590
15. Tsurutani J West KA Sayyah J Gills JJ Dennis PA Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy Cancer Res 2005, 65(18):8423-8432 10.1158/ 0008-5472.CAN-05-0058 16166321
16. Meynard D Le Morvan V Bonnet J Robert J Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity Oncol Rep 2007, 17(5):1213-1221 17390068
17. Ueki K Yamamoto-Honda R Kaburagi Y Yamauchi T Tobe K Burgering BM Coffer PJ Komuro I Akanuma Y Yazaki Y Kadowaki T Potential role of protein kinase B in insulin-induced glucose transport, glycogen synthesis, and protein synthesis J Biol Chem 1998, 273(9):5315-5322 10.1074/ jbc.273.9.5315 9478990
18. Fasolo A Sessa C mTOR inhibitors in the treatment of cancer Expert Opin Investig Drugs 2008, 17(11):1717-1734 10.1517/13543784.17.11.1717 18922108
19. Tanaka C O'Reilly T Kovarik JM Shand N Hazell K Judson I Raymond E Zumstein-Mecker S Stephan C Boulay A Hattenberger M Thomas G Lane HA Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data J Clin Oncol 2008, 26(10):1596-1602 18332467
20. Beuvink I Boulay A Fumagalli S Zilbermann F Ruetz S O'Reilly T Natt F Hall J Lane HA Thomas G The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation Cell 2005, 120(6):747-759 10.1016/j.cell.2004.12.040 15797377
21. Mabuchi S Altomare DA Cheung M Zhang L Poulikakos PI Hensley HH Schilder RJ Ozols RF Testa JR RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res 2007, 13(14):4261-4270 10.1158/1078-0432.CCR-06-2770 17634556
22. O'Reilly KE Rojo F She QB Solit D Mills GB Smith D Lane H Hofmann F Hicklin DJ Ludwig DL Baselga J Rosen N mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 2006, 66(3):1500-1508 10.1158/0008-5472.CAN-05-2925 16452206